RT Journal Article
T1 Role of Oestrogen Receptors on the Modulation of NADPH‐Diaphorase‐Positive Cell Number in Supraoptic and Paraventricular Nuclei of Ovariectomised Female Rats
A1 Grassi, Daniela
A1 Lagunas García, Luisa Natalia
A1 Amorim, Miguel
A1 Pinos, Helena
A1 Panzica, GianCarlo
A1 Garcia‐Segura, Luis
A1 Collado, Paloma
AB Modulation of the nitric oxide producing system (demonstrated via the NADPH-diaphorase histochemical reaction) by oestradiol has been established in several structures of the rat brain. The present study aimed to explore the possible regulation of NADPH-diaphorase activity by oestradiol in neurones of the supraoptic (SON) and paraventricular (PVN) nuclei and the role of oestrogen receptors (ERα and ERβ) in this regulation. Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERα agonist-PPT [4,4',4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERβ agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERα antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERβ antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol). The number of NADPH-diaphorase positive elements in the SON and the PVN was modulated by both ERs but, depending on the nucleus, ERα and ERβ ligands induced different effects. These results suggest that the regulation of nitrergic system by ERs may play a role in the control of oestrogen-dependent physiological mechanisms regulated by the SON and the PVN.
PB Wiley
SN 0953-8194
YR 2013
FD 2013
LK https://hdl.handle.net/20.500.14352/95231
UL https://hdl.handle.net/20.500.14352/95231
LA eng
NO Grassi, D., et al. «Role of Oestrogen Receptors on the Modulation of NADPH‐Diaphorase‐Positive Cell Number in Supraoptic and Paraventricular Nuclei of Ovariectomised Female Rats». Journal of Neuroendocrinology, vol. 25, n.o 3, marzo de 2013, pp. 244-50. https://doi.org/10.1111/j.1365-2826.2012.02387.x.
DS Docta Complutense
RD 11 abr 2025